News articles about Adamis Pharmaceuticals (NASDAQ:ADMP) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Adamis Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 46.1712785268933 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
ADMP has been the subject of several recent research reports. B. Riley set a $10.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 15th. Maxim Group set a $14.00 price target on shares of Adamis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 5th. ValuEngine lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 30th. Finally, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Adamis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $10.33.
Shares of Adamis Pharmaceuticals (NASDAQ ADMP) traded up $0.10 during trading on Thursday, hitting $4.20. 399,204 shares of the stock were exchanged, compared to its average volume of 597,667. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.79 and a current ratio of 3.93. Adamis Pharmaceuticals has a 52-week low of $2.80 and a 52-week high of $6.45. The stock has a market cap of $138.56, a P/E ratio of -6.00 and a beta of 0.33.
COPYRIGHT VIOLATION NOTICE: “Adamis Pharmaceuticals (ADMP) Receiving Somewhat Favorable News Coverage, Study Finds” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/18/adamis-pharmaceuticals-admp-receiving-somewhat-favorable-news-coverage-study-finds.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.